Study of young people with myeloproliferative neoplasia and their outcomes
Builds a national database of patients under 30 with myeloproliferative neoplasia.
Plain-language title generated from the registry record
Registry title: Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
Key facts
- Where
- Brest, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people diagnosed with a myeloproliferative neoplasm (a type of blood cancer, not CML) before the age of 30. Their data and samples are collected in a national database.
- Age
- 0 to 30 years. The record also asks for patients of legal age at the time of joining.
- Sex
- All sexes can join.
- Disease stage
- Myeloproliferative neoplasm that is not CML: PV, TE, MFP or PreMF, diagnosed before age 30 by the 2016 WHO criteria.
Main reasons for not taking part
- Adult patients who refuse to take part
- Patients under legal protection (guardianship, curatorship, etc.)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 30 years old?
Source: NCT06715267, who can take part
Where in France
- CHU de BrestBrest, FranceContact: Jean-Christophe IANOTTOTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Brest
- Trial code
- NCT06715267
- Record updated
- 4 December 2024
- Original description
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.Read full original descriptionShow less
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Inclusion: Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria; Signature of the consent form for participation in the FIMBANK project; Agreement to participate in the VYP study; Patient of legal age at the time of inclusion in VYP; Patient affiliated to a social security scheme.
Exclusion: Refusal to participate by patients of full age; Patient under legal protection (guardianship, curatorship, etc.).